LEERINK SWANN

Bugs and Drugs: The Future of Molecular Diagnostics Roundtable Conference
Thursday, April 3, 2008

Daniel H. Farkas PhD, HCLD, CC, CLSp(MB), FACB

Dr. Farkas is the Executive Director of the Center for Molecular Medicine in Grand Rapids, MI. At the Center, he has established an advanced molecular pathology laboratory in support of 21st century molecular and proteomic diagnostic applications and clinical trials for both the diagnostics and pharmaceutical industries. Dr. Farkas is currently on the faculty at Michigan State University in East Lansing, MI and has also been on the faculty of Baylor College of Medicine and Weill Medical College of Cornell University. Previously, he was Director of Molecular Pathology at The Methodist Hospital in Houston. From 1998-2002, Dr. Farkas was Director of Clinical Diagnostics at Clinical Micro Sensors (acquired by Motorola in 2000) and played a significant role in the ultimate FDA approval of a DNA-chip based test for cystic fibrosis mutation detection. Dr Farkas is a Consultant to and was a Member of the Clinical and Molecular Genetics Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA). In 2007, he was a Member of the Program Committee of Clinical and Laboratory Genomic and Genetic Standards, sponsored by the Drug Information Association and the FDA. He has also served on the CDC Expert Panel on Quality Control Materials for Genetic Testing. Dr. Farkas was the first person to be certified by the American Board of Bioanalysis (ABB; he now serves on their Board) in Molecular Diagnostics and holds the credentials of High Complexity Clinical Laboratory Director (HCLD) and Clinical Consultant (CC) from ABB. He is a former President of the Association for Molecular Pathology and currently serves on the American Association for Clinical Chemistry (AACC) Board of Directors.

Christine Ginocchio PhD, MT

Dr. Ginocchio's major professional interests include the development of molecular diagnostics for infectious diseases, antimicrobial resistance, and MRSA. She is currently the Director of Clinical Microbiology and Virology, Molecular Diagnostics, and HIV Testing services for the North Shore-Long Island Jewish Health System Laboratories (NSHS), in Lake Success, NY. The NSHS core laboratory facility performs routine and reference diagnostic testing for 11 hospitals, including two university tertiary care facilities (North Shore University Hospital, Long Island Jewish Medical Center), Schneider's Children's Hospital, 8 community hospitals, 35 nursing homes, hospital-affiliated clinics, and over 300 physician offices. Dr. Ginocchio is also an Associate Professor in the Department of Microbiology and Genetics at the State University of New York at Stony Brook; and an Adjunct Clinical Professor in the School of Health Professions at Long Island University in Bronxville. Dr. Ginocchio's microbiology lab test volume is approximately 500,000 specimens per year and her molecular diagnostics test volume is approximately 150,000 specimens per year. She also serves on the Infection Control Committee, Pharmacy and Therapeutics Committee, and the North Shore-LIJ Health System Laboratory Medical Advisory Board. Dr. Ginocchio is an Associate Editor for Journal of Clinical Virology, Manual of Clinical Microbiology and is on the editorial board of Clinical Microbiology Reviews. She serves on the Scientific Advisory Boards for GenProbe, Luminex, and Siemens.

Nicholas Potter PhD

Dr. Potter is currently the Chief Scientific Officer and Director of Molecular Diagnostics at Molecular Pathology Laboratory Network, Inc. in Maryville TN, which offers molecular diagnostics and cytogenetic tests and services. Dr. Potter is also a Clinical Associate Professor of Pathology at the University of Tennessee Medical Center. He is a Fellow of the American College of Medical Genetics and board-certified in Clinical Molecular Genetics by the American Board of Medical Genetics. Dr. Potter is a Member of the Molecular Genetic Test Development and Advisory Committee, for the American Board of Pathology. He is also a Member of the Clinical Molecular Genetics Item Review Committee for the American Board of Medical Genetics. Dr. Potter's major professional interests include molecular diagnostics, neurogenetics, pharmacogenetics, and nucleic acid testing technology innovations. He is also knowledgeable in regards to molecular coagulation and HCV genotyping, and has extensive experience with Huntington's disease testing.